array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2445)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(94) "RBC sees buying opportunity following Regeneron’s ‘overdone DOJ downside’ - TipRanks.com"
["snippet_en"]=>
string(167) "RBC Capital notes that the Department of Justice has filed a complaint against Regeneron, accusing the company of fraudulently inflating Medicare reimbursement rate..."
["url"]=>
string(108) "https://www.tipranks.com/news/the-fly/rbc-sees-buying-opportunity-following-regenerons-overdone-doj-downside"
["image_url"]=>
NULL
["source"]=>
string(12) "tipranks.com"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(2) {
[0]=>
string(10) "Litigation"
[1]=>
string(10) "Complaints"
}
}
[1]=>
array(7) {
["title_en"]=>
string(78) "US Justice Department files suit against Regeneron for fraudulent drug pricing"
["snippet_en"]=>
string(155) "The U.S. Department of Justice said Wednesday that it has filed a lawsuit against Regeneron Pharmaceuticals for falsely reporting average selling prices..."
["url"]=>
string(187) "https://ch.marketscreener.com/kurs/aktie/REGENERON-PHARMACEUTICALS-10649/news/US-Justizministerium-erhebt-Klage-gegen-Regeneron-wegen-betrugerischer-Preisgestaltung-bei-Medikame-46408681/"
["image_url"]=>
NULL
["source"]=>
string(18) "marketscreener.com"
["publication_date"]=>
string(10) "2024-04-10"
["categories"]=>
array(3) {
[0]=>
string(5) "Legal"
[1]=>
string(5) "Fraud"
[2]=>
string(10) "Litigation"
}
}
[2]=>
array(7) {
["title_en"]=>
string(71) "US appeals court revives Regeneron's antitrust lawsuit against Novartis"
["snippet_en"]=>
string(258) "NEW YORK (Reuters) -A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S."
["url"]=>
string(76) "https://ca.news.yahoo.com/us-appeals-court-revives-regenerons-141546622.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/0ca9dd7e-b0ed-441e-96e8-bb1697c60801"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(7) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(14) "Product Launch"
[2]=>
string(8) "Verdicts"
[3]=>
string(9) "Antitrust"
[4]=>
string(5) "Legal"
[5]=>
string(10) "Litigation"
[6]=>
string(46) "Management of Legal and Regulatory Environment"
}
}
[3]=>
array(7) {
["title_en"]=>
string(90) "Regeneron scores victory against Eylea biosimilar as expedited trial tactic pays dividends"
["snippet_en"]=>
string(67) "Meanwhile, the innovator has sued several more would-be competitors"
["url"]=>
string(121) "https://www.iam-media.com/article/regeneron-scores-victory-against-eylea-biosimilar-expedited-trial-tactic-pays-dividends"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/9992b541-96a8-4c88-99dc-d7dbe4424876"
["source"]=>
string(13) "iam-media.com"
["publication_date"]=>
string(10) "2024-01-11"
["categories"]=>
array(1) {
[0]=>
string(10) "Litigation"
}
}
[4]=>
array(7) {
["title_en"]=>
string(64) "Regeneron Sues Celltrion to Block Biosimilar of Top-Seller Eylea"
["snippet_en"]=>
string(234) "Regeneron Pharmaceuticals Inc. sued Celltrion Inc. to block its proposed biosimilar version of Eylea, alleging it infringes 38 patents for the retinal-disease treatment responsible for more than half of the drugmaker’s 2022 revenue."
["url"]=>
string(101) "https://news.bloomberglaw.com/ip-law/regeneron-sues-celltrion-to-block-biosimilar-of-top-seller-eylea"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/46b0accd-1555-4f96-a527-f86b984fdb21"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2023-11-09"
["categories"]=>
array(2) {
[0]=>
string(5) "Legal"
[1]=>
string(10) "Litigation"
}
}
[5]=>
array(7) {
["title_en"]=>
string(64) "Regeneron Gets Judge to Certify Charity Kickback Suit for Appeal"
["snippet_en"]=>
string(196) "Regeneron Pharmaceuticals Inc. showed that an appeals court needs to address how closely connected a kickback must be to an allegedly false claim before the a suit against it can proceed to trial."
["url"]=>
string(114) "https://news.bloomberglaw.com/federal-contracting/regeneron-gets-judge-to-certify-charity-kickback-suit-for-appeal"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fe557120-750c-45b0-ba4e-e442682cf4fa"
["source"]=>
string(16) "bloomberglaw.com"
["publication_date"]=>
string(10) "2023-10-26"
["categories"]=>
array(4) {
[0]=>
string(5) "Legal"
[1]=>
string(10) "Litigation"
[2]=>
string(8) "Verdicts"
[3]=>
string(46) "Management of Legal and Regulatory Environment"
}
}
[6]=>
array(7) {
["title_en"]=>
string(170) "More US States Take on Eli Lilly in Court Over Proposed Insulin Pricing Settlement + Regeneron's High Dose Eylea Wins FDA Approval – Xtalks Life Science Podcast Ep. 125"
["snippet_en"]=>
string(295) "In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin"
["url"]=>
string(182) "https://xtalks.com/more-us-states-take-on-eli-lilly-in-court-over-proposed-insulin-pricing-settlement-regenerons-high-dose-eylea-wins-fda-approval-xtalks-life-science-podcast-ep-125/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b8e7799f-62e6-42e8-904b-e0e36483d2c3"
["source"]=>
string(10) "xtalks.com"
["publication_date"]=>
string(10) "2023-08-30"
["categories"]=>
array(4) {
[0]=>
string(5) "Legal"
[1]=>
string(10) "Litigation"
[2]=>
string(11) "Acquisition"
[3]=>
string(16) "Case Settlements"
}
}
[7]=>
array(7) {
["title_en"]=>
string(102) "Court Permits Addition Of Inventor To A Patent That Is Subject Of Ongoing Litigation - Patent - Canada"
["snippet_en"]=>
string(188) "In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron's application to add an inventor to its issued patent, which was the subject of pending..."
["url"]=>
string(38) "https://www.mondaq.com/Article/1333428"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/165ab028-1b40-4167-9a0b-4e2fd5aa5498"
["source"]=>
string(10) "mondaq.com"
["publication_date"]=>
string(10) "2023-06-23"
["categories"]=>
array(3) {
[0]=>
string(5) "Legal"
[1]=>
string(10) "Litigation"
[2]=>
string(8) "Verdicts"
}
}
[8]=>
array(7) {
["title_en"]=>
string(69) "Regeneron boss backs attempt to block $28bn Horizon Therapeutics deal"
["snippet_en"]=>
string(113) "Leonard Schleifer supportive of US Federal Trade Commission’s lawsuit against largest pharma sector M&A of 2022"
["url"]=>
string(116) "https://www.irishtimes.com/business/2023/05/17/regeneron-boss-backs-attempt-to-block-28bn-horizon-therapeutics-deal/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/2fcbea1b-1fe3-4e07-abb9-fa56a4b3fdc4"
["source"]=>
string(14) "irishtimes.com"
["publication_date"]=>
string(10) "2023-05-17"
["categories"]=>
array(2) {
[0]=>
string(5) "Legal"
[1]=>
string(10) "Litigation"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(101)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(30)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2445 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
RBC Capital notes that the Department of Justice has filed a complaint against Regeneron, accusing the company of fraudulently inflating Medicare reimbursement rate...
The U.S. Department of Justice said Wednesday that it has filed a lawsuit against Regeneron Pharmaceuticals for falsely reporting average selling prices...
NEW YORK (Reuters) -A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness. The 2nd U.S.
Regeneron Pharmaceuticals Inc. sued Celltrion Inc. to block its proposed biosimilar version of Eylea, alleging it infringes 38 patents for the retinal-disease treatment responsible for more than half of the drugmaker’s 2022 revenue.
Regeneron Pharmaceuticals Inc. showed that an appeals court needs to address how closely connected a kickback must be to an allegedly false claim before the a suit against it can proceed to trial.
In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin
In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron's application to add an inventor to its issued patent, which was the subject of pending...
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
